According to the website of the State Drug Administration, a new generation of innovative drugs developed by Yiyi Biology, a new generation of long-acting granulocyte colony stimulating factor (G-CSF), "Abergerstine α injection" (trade name "Yilishu"), has been officially approved for listing. Prior to this, Zhengda Tianqing Pharmaceutical Group, the core enterprise of China Biopharmaceutical, has signed a commercial cooperation agreement with Yiyi Bio to obtain all the intellectual property rights and exclusive commercial rights and interests of Yilishu in China. This also marks the official entry of China's biopharmaceutical into the 10 billion liter white medicine market. Xie Chengrun, chief executive of China Biopharmaceutical and chairman of Zhengda Tianqing Pharmaceutical Group, said: with the listing of Yilishu, we are confident that we will bring more high-quality and economical treatment to more cancer patients.